These first two elements are arguably the most important, but there is a third element that is rarely discussed up front, but also plays a significant role… Cost vs value.
It is important that your funds go a long way especially if you are a smaller biotech company, so it is imperative that you work with an organization that is as cost-conscience as you are. After a number of conversations with our clients and colleagues, we have established methods that allow us to be more cost-effective, and we have implemented these changes throughout the process. We have systems in place to ensure we are not duplicating efforts, saving you time and money.
We are absolutely transparent with our clients. There is a very simple process we go through in determining the cost of your PK studies. This process includes:
Discussed previously was how Attentive is a better option than the larger CRO’s. One of the ways we prove that is by being a consistently more cost-efficient provider. Because Attentive does not have the high corporate overheads as compared to larger organizations, we can – and have always – provided a very cost-efficient business line for our pharmacokinetic clients.
To be cost efficient in PK work, we use established colonies to allow you to begin your studies immediately without first purchasing the test systems and maintaining the test systems in quarantine. By already having test systems in place, you are in control of when the study starts.
You have choices to make for your project. Determining the right CRO is key among your resolutions. As a boutique provider of nonclinical in-vivo services to the industry, Attentive will be expanding its ability to serve our customers with investments in our people, equipment and facilities. Our promise to you is to continue to provide cost efficient, quality services in a timely manner whilst paying attention to you and your company's needs. We have a variety of programs that fit your mission. We invite you to take a closer look at Attentive - you'll be happy with what you find.